Anticoagulation therapy is central to the management of thromboembolic disorders, and the
use of direct oral anticoagulants offers several advantages over standard therapy with …

The advent of direct oral anticoagulants (DOACs) has revolutionized anticoagulation
management in both stroke prevention and venous thromboembolism (VTE) …

Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major
step forward in the treatment of acute-and long-term prevention of venous thrombo …

The issue of optimal duration of oral anticoagulant therapy after a first episode of venous
thromboembolism is still unresolved. However, recent data suggest that short (6 weeks to 3 …

Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide. Strokes that occur
as a complication of AF are usually more severe and associated with a higher disability or …

Administration of oral anticoagulants is the cornerstone in the prevention of (chronic)
morbidity and mortality due to arterial thromboembolic stroke (1) and, on the venous side, of …

Several direct oral anticoagulants (DOACs) have been developed that dose-dependently
inhibit thrombin or activated factor X and offer potential advantages over vitamin K …

Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and
provide advantages over existing agents. As with all anticoagulants, management protocols …

Anticoagulation therapy is recommended for preventing, treating, and reducing the
recurrence of venous thromboembolism, and preventing stroke in persons with atrial …

Because differences in renal function can affect the efficacy and safety of direct oral
anticoagulants, prescribing an appropriate dose based on renal function is critical …